ARDX - Ardelyx, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.40
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.40
Open4.40
Bid4.30 x 400
Ask4.85 x 5500
Day's Range4.35 - 4.50
52 Week Range3.58 - 8.65
Volume146,791
Avg. Volume718,817
Market Cap272.706M
Beta1.80
PE Ratio (TTM)N/A
EPS (TTM)-1.12
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.33
Trade prices are not sourced from all markets
  • ACCESSWIRE26 days ago

    Free Technical Reports on Array BioPharma and Three Additional Biotech Equities

    Under observation are these four equities: Ardelyx Inc. (NASDAQ: ARDX), Array BioPharma Inc. (NASDAQ: ARRY), Audentes Therapeutics Inc. (NASDAQ: BOLD), and Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH). All you have to do is sign up today for this free limited time offer by clicking the link below.

  • GlobeNewswire2 months ago

    Consolidated Research: 2018 Summary Expectations for CorVel, Consol Energy, Ardelyx, Aevi Genomic Medicine, Proofpoint, and Brink's — Fundamental Analysis, Key Performance Indications

    NEW YORK, May 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CorVel ...

  • PR Newswire2 months ago

    Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference

    FREMONT, Calif., May 29, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a company overview at the Jefferies Global Healthcare Conference on Tuesday, June 5, 2018 at 2:30 p.m. ET in New York City. To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. Ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. Ardelyx's renal pipeline includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease.

  • Why Ardelyx Inc. Is Down by Double Digits for a Second Day in a Row
    Motley Fool2 months ago

    Why Ardelyx Inc. Is Down by Double Digits for a Second Day in a Row

    The buyers for its secondary stock offering weren't willing to pay up for the biotech.

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks Hitting 52-week highs on May 22) ArQule, Inc. (NASDAQ: ARQL ) AstraZeneca plc (ADR) (NYSE: ...

  • PR Newswire2 months ago

    Ardelyx Announces Pricing of Public Offering of Common Stock

    FREMONT, Calif., May 22, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $4.00 per share, before underwriting discounts and commissions, for gross proceeds of $50,000,000. In addition, the Company has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less underwriting discounts and commissions. Ardelyx currently expects to use its existing cash, cash equivalents and short-term investments and the net proceeds of the offering to support its clinical development and pre-commercialization efforts for tenapanor for the treatment of hyperphosphatemia in patients with end-stage renal disease who are on dialysis, including the ongoing second Phase 3 clinical trial evaluating tenapanor for such indication, its manufacturing efforts for tenapanor, research and development efforts for its RDX013 program, the preparation and submission of a New Drug Application for tenapanor for irritable bowel syndrome with constipation and for general corporate purposes and working capital.

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks Hitting 52-week highs on May 21) AstraZeneca plc (ADR) (NYSE: AZN ) (FDA approved its ...

  • PR Newswire2 months ago

    Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank

    FREMONT, Calif., May 21, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX), today announced it has entered into a $50.0 million senior secured term loan facility with Solar Capital Ltd. and the Life Sciences Group at Bridge Bank, a division of Western Alliance Bank. "With this additional capital, we have strengthened our position to execute our business strategy of developing disruptive treatments for renal diseases," said Mike Raab, president and chief executive officer of Ardelyx. The loan agreement with Solar Capital Ltd. and Bridge Bank provides for a $50.0 million senior secured term loan facility with a maturity date of November 1, 2022, or approximately 54 months after its initiation, with an interest rate of 7.45 percent plus the 30-day LIBOR.

  • PR Newswire2 months ago

    Ardelyx Announces Proposed Public Offering of Common Stock

    FREMONT, Calif., May 21, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX), today announced that it has commenced an underwritten public offering of up to $50,000,000 of shares of its common stock. All of the shares to be sold in the offering will be offered by Ardelyx. In addition, Ardelyx intends to grant the underwriters of the offering the right for a period of 30 days to purchase up to an additional $7,500,000 of shares of common stock at the public offering price, less underwriting discounts and commissions.

  • Associated Press2 months ago

    Ardelyx: 1Q Earnings Snapshot

    The Fremont, California-based company said it had a loss of 36 cents per share. The biotechnology company posted revenue of $2.3 million in the period. Ardelyx shares have fallen 23 percent since the beginning ...

  • PR Newswire2 months ago

    Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights

    On Track to Submit NDA for Tenapanor in IBS-C in Second Half of 2018 Enrollment Underway in Second Registration Study of Tenapanor for Hyperphosphatemia FREMONT, Calif. , May 8, 2018 /PRNewswire/ -- Ardelyx, ...

  • PR Newswire4 months ago

    Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada

    FREMONT, Calif., March 19, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced a license agreement with Knight Therapeutics, Inc. (GUD.TO) (Knight) that provides Knight with exclusive rights to commercialize tenapanor in Canada. Tenapanor is Ardelyx's oral, first-in-class small molecule treatment that has completed Phase 3 development for irritable bowel syndrome with constipation (IBS-C) and is being evaluated in a second Phase 3 study for hyperphosphatemia.

  • Associated Press4 months ago

    Ardelyx posts 4Q profit

    The Fremont, California-based company said it had net income of 21 cents per share. The biotechnology company posted revenue of $42 million in the period. For the year, the company reported that its loss ...

  • PR Newswire4 months ago

    Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors

    Enrollment Underway in Second Registration Study of Tenapanor for Hyperphosphatemia NDA for Tenapanor for IBS-C on Track for Submission in Second Half of 2018 FREMONT, Calif. , March 14, 2018 /PRNewswire/ ...

  • PR Newswire5 months ago

    Ardelyx Announces Departure of Chief Scientific Officer

    FREMONT, Calif., Feb. 12, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that Jeremy Caldwell, Ph.D., chief scientific officer, will be leaving the company, effective February 16, 2018, to pursue a position as chief executive officer of an early stage biotech start-up company based in San  Diego. "Jeremy has been a tremendous asset to Ardelyx, and I am incredibily grateful for his many contributions to the company and our programs over the years," said Mike Raab, president and chief executive officer of Ardelyx. "My time with Ardelyx has been extremely rewarding, and I'm proud of the many accomplishments of this team," said Jeremy.

  • PR Newswire5 months ago

    Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference

    FREMONT, Calif., Feb. 8, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 2:00 p.m. ET on Thursday, Feb. 15, 2018 in New York City. To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing differentiated, minimally systemic medicines.

  • Best NasdaqGM Growth Stocks
    Simply Wall St.6 months ago

    Best NasdaqGM Growth Stocks

    Companies that have significant growth prospects for profitability and returns can add tangible upside to your portfolio. Ardelyx and eMagin are examples of many potential outperformers that analysts are bullishRead More...

  • 5 Great Breakout Stocks Offering Superlative Returns
    InvestorPlace6 months ago

    5 Great Breakout Stocks Offering Superlative Returns

    In order to select the right breakout stock one has to first calculate its support and resistance level. A support level is the lower bound for stock movements while a resistance level refers to the maximum price which it trades within over a considerable period. In other words, the demand for a stock is at its lowest at its support level, which means most traders are willing to sell it.

  • Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service
    Zacks6 months ago

    Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service

    Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service

  • 5 Great Breakout Stocks Offering Superlative Returns
    Zacks6 months ago

    5 Great Breakout Stocks Offering Superlative Returns

    This method involved zeroing in on those stocks whose prices are varying within a narrow band.

  • Can The Uptrend Continue for Ardelyx (ARDX)?
    Zacks7 months ago

    Can The Uptrend Continue for Ardelyx (ARDX)?

    Investors certainly have to be happy with Ardelyx Inc (ARDX) and its short term performance

  • Ardelyx Inc (NASDAQ:ARDX): Is It A Good Long Term Opportunity?
    Simply Wall St.7 months ago

    Ardelyx Inc (NASDAQ:ARDX): Is It A Good Long Term Opportunity?

    The most recent earnings release Ardelyx Inc’s (NASDAQ:ARDX) announced in September 2017 suggested that losses became smaller relative to the prrior year’s level as a result of recent tailwinds InvestorsRead More...

  • PR Newswire7 months ago

    Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference

    FREMONT, Calif., Jan. 3, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a company overview at the J.P. Morgan 36th Annual Healthcare Conference on Wednesday, Jan. 10, 2018 at 10 a.m. PT. To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor page of the Ardelyx website at ir.ardelyx.com. Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing differentiated, minimally systemic medicines.